Adilson started his career in the pharmaceutical industry in 1988, working on different positions of increasing responsibilities in Marketing and Sales. In 1998 he joined Parke-Davis into a startup project. In 1999 he was assigned to Uruguay and after the merger with Pfizer, Adilson became Pfizer Uruguay General Manager until 2002 when he took over a regional position based in Argentina, firstly as Commercial Director then as Sales and Marketing Director. In 2007, Adilson return to Brazil to lead a Field Force reorganization. In 2008, Adilson became PCBU (Primary Care Business Unit) Director. During Pfizer and Wyeth integration, Adilson was assigned to develop and lead the creation of EPBU (Established Products Business Unit), as well as participated on the project of Teuto’s acquisition, lately appointed as EPBU Director and Teuto’s Integration Officer and also Teuto’s Board of Director Member. In 2015 Adilson joined a regional position as LATAM Biosimilar Commercial Lead, starting the development of strategies and commercial planning for the upcoming biosimilar business in Latin America. In 2016 he was appointed as the Pfizer Biosimilar Business Unit Director, responsible for creating a new Business Unit for Biosimilar portfolio; defining business strategies and launch the first mAB biosimilar in the market (Remsima) as well as developing and executing all market and commercial strategies for the upcoming new biosimilar molecules within Pfizer portfolio. Adilson holds an MBA by IAE-Escuela de Dirección y Negocios in Buenos Aires, Argentina and a degree in Marketing & Advertising by PUCCAMP – University of Campinas, Brazil and other degrees in Management and Coaching Programs such as Pharmaceutical Marketing Development by INCAE, Costa Rica, Managerial Issues in the Global Enterprise by Thunderbird International, Glendale, Arizona.